Nebivolol Hydrochloride

盐酸奈必洛尔

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameNebivolol Hydrochloride
Drug Alias Name塞利洛尔盐酸盐Nebivololum奈比洛尔yaya奈比洛尔奈必洛尔 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-1 adrenergic receptor antagonists
TargetsBeta-1 adrenergic receptor
Therapy Area/IndicationsDiabetic peripheral neuropathyDiabetes MellitusEssential Hypertension +[6] 
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryGermany
Original Approved Date1997/01/01
Country/TerritoryUnited StatesGermanyEgypt +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBio-innova Co LtdMenarini GroupAllergan Plc +[9] 
Inactive CompaniesMylan Bertek Pharmaceuticals IncThe University Of ChicagoThomas Jefferson University +[4] 
Active IndicationsDiabetic peripheral neuropathyEssential HypertensionHypertension +[4] 
Inactive IndicationsDiabetes MellitusPeripheral Arterial Disease

Other Information

ATC CodeC07AB12
Related LinksWikipediaDrugBankKEGG